Fast Five Quiz: Type 2 Diabetes Incretin-Based Therapy

Romesh Khardori, MD, PhD


June 24, 2021

Both DPP-4 inhibitors and GLP-1 receptor agonists have been shown to significantly lower A1c in patients taking either a single oral antidiabetic drug or two or more oral antidiabetic drugs. These therapies also improved both fasting and postprandial hyperglycemia and increased the number of patients who reached a target A1c ≤ 7%.

GLP-1 receptor agonists more effectively lower glycemia than DPP-4 inhibitors, and compared with sodium-glucose cotransporter 2 (SGLT2) inhibitors and thiazolidinediones, DPP-4 inhibitors are for the most part lesser glycemia-lowering agents.

Long-acting GLP-1 receptor agonists more effectively lower A1c than short-acting agents.

Learn more about the treatment and management of type 2 diabetes.


Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.
Post as: